Table 3.

Ongoing adjuvant phase III trials evaluating the addition of bevacizumab for the treatment of early breast cancer.

Identifier	Study	N	Study population	Study design
NCT00528567	BEATRICE	2,583	Triple negative BC	Standard CT versus Standard CT + BEV for 1 year
NCT00887536	NSABP B-46	3,900	HER2 negative N+ or high risk N−	Docetaxel/cyclophosphamide × 6 versus Docetaxel/doxorubicin/cyclophosphamide × 6 versus Docetaxel/cyclophosphamide/BEV × 6 (followed by BEV alone until 1 year)
NCT00625898	BETH	3,509	HER2 positive N+ or high risk N−	Docetaxel/carboplatin/TRAST × 6 (followed by TRAST alone until 1 year) versus Docetaxel/carboplatin/TRAST/BEV × 6 (followed by TRAST/BEV until 1 year) versus Docetaxel [×3]/FEC [×3]/TRAST × 6 (followed by TRAST alone until 1 year) versus Docetaxel [×3]/FEC [×3]/TRAST/BEV × 6 (followed by TRAST/BEV until 1 year)
NCT00433511	ECOG 5103	4,950	HER2 negative N+ or high risk N−	AC [×4]/weekly paclitaxel [×12]/placebo versus AC [×4]/weekly paclitaxel [×12]/BEV versus AC [×4]/weekly paclitaxel [×12]/BEV (followed by BEV alone until 1 year)

Identifiers are from clinicaltrials.gov website.

Abbreviations: n: estimated number of patients; N+: lymph nodes positive; N−: lymph nodes negative; CT: chemotherapy; BEV: bevacizumab; TRAST: trastuzumab; FEC: 5-fluorouracil/epirubicin/cyclophosphamide; AC: adriamycin/cyclophosphamide.